- Home
- WRBY vs KROS Comparison
WRBY vs KROS Comparison
Compare WRBY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRBY
- KROS
- Stock Information
- Founded
- WRBY 2010
- KROS 2015
- Country
- WRBY United States
- KROS United States
- Employees
- WRBY N/A
- KROS N/A
- Industry
- WRBY Ophthalmic Goods
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- WRBY Health Care
- KROS Health Care
- Exchange
- WRBY Nasdaq
- KROS Nasdaq
- Market Cap
- WRBY 2.9B
- KROS 633.5M
- IPO Year
- WRBY 2021
- KROS 2020
- Fundamental
- Price
- WRBY $25.36
- KROS $15.92
- Analyst Decision
- WRBY Buy
- KROS Buy
- Analyst Count
- WRBY 10
- KROS 11
- Target Price
- WRBY $21.00
- KROS $68.83
- AVG Volume (30 Days)
- WRBY 1.6M
- KROS 1.9M
- Earning Date
- WRBY 02-26-2025
- KROS 02-26-2025
- Dividend Yield
- WRBY N/A
- KROS N/A
- EPS Growth
- WRBY N/A
- KROS N/A
- EPS
- WRBY N/A
- KROS N/A
- Revenue
- WRBY $742,527,000.00
- KROS $651,000.00
- Revenue This Year
- WRBY $16.87
- KROS $224.66
- Revenue Next Year
- WRBY $13.10
- KROS N/A
- P/E Ratio
- WRBY N/A
- KROS N/A
- Revenue Growth
- WRBY 13.47
- KROS 8037.50
- 52 Week Low
- WRBY $11.35
- KROS $15.33
- 52 Week High
- WRBY $25.89
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- WRBY 64.03
- KROS 22.66
- Support Level
- WRBY $23.76
- KROS $15.33
- Resistance Level
- WRBY $25.89
- KROS $17.25
- Average True Range (ATR)
- WRBY 1.01
- KROS 1.37
- MACD
- WRBY -0.12
- KROS -0.48
- Stochastic Oscillator
- WRBY 79.77
- KROS 10.31
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.